Skip to main content

Advertisement

SpringerLink
Log in

Chemoresistance in gliomas

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Despite improved knowledge and advanced treatments of gliomas, the overall survival rate for glioma patients remains low. Gliomas comprise of significant cell heterogeneity that contains a large number of multidrug resistant (MDR) phenotypes and cancer stem cells (CSCs), a combination that may contribute to the resistance to treatment. This article reviews the MDR related genes, major-vault protein (MVP), anti-apoptotic protein (Bcl-2) and the molecular mechanisms that may contribute to chemoresistance, in addition to the upregulated MDR phenotypes present in CSCs that has recently been identified in gliomas. Moreover, future potential therapies that modulate MDR phenotypes and CSCs are also reviewed. An improved understanding of MDR may lead to a combined treatment, targeting both CSCs and their protective MDR phenotypes leading eventually to attractive strategies for the treatment of gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn M J, Brenner H, Esteve J (2004) Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 90:1367–1373

    PubMed  CAS  Google Scholar 

  2. Darling J (2004) In vitro culture of malignant brain tumors. In: Pfragner R, Freshney I (eds) Culture of human tumor cells. Wiley-Liss Inc., Verlag GMbH, pp 349–372

    Google Scholar 

  3. Bredel M (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35:161–204

    PubMed  CAS  Google Scholar 

  4. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284

    PubMed  CAS  Google Scholar 

  5. Kroll DJ (1995) Circumventing antineoplastic drug resistance: when tumor cells just say “no” to drugs. Am J Pharm Educ 59:184–191

    Google Scholar 

  6. Biemans-Oldehinkel E, Doeven MK, Poolman B (2006) ABC transporter architecture and regulatory roles of accessory domains. FEBS Lett 580:1023–1035

    PubMed  CAS  Google Scholar 

  7. Bunting KD (2002) ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells. 20:11–20

    PubMed  CAS  Google Scholar 

  8. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156–1166

    PubMed  CAS  Google Scholar 

  9. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58

    PubMed  CAS  Google Scholar 

  10. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538–4542

    PubMed  CAS  Google Scholar 

  11. Spiegl-Kreinecker S (2002) Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance Protein 1 in human brain tumor cells and astrocytes. J Neuro-Oncology 57:27–36

    Google Scholar 

  12. Bahr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W (2003) P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol 13:482–494

    Article  PubMed  Google Scholar 

  13. Mousseau M, Schaerer R, Pasquier B, Chauvin C, Nissou MF, Chaffanet M, Plantaz D, Benabid A (1993) A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 29A:753–759

    PubMed  CAS  Google Scholar 

  14. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, Kuwano M, Hori S (1998) Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 40L:11–18

    Google Scholar 

  15. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614

    Article  PubMed  CAS  Google Scholar 

  16. Chou PM, Reyes-Mugica M, Barquin N, Yasuda T, Tan X, Tomita T (1995) Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients. Pediatr Neurosurg 23:283–291

    PubMed  CAS  Google Scholar 

  17. Korshunov A, Sycheva R, Timirgaz V, Golanov A (1999a) Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 45:219–227

    PubMed  CAS  Google Scholar 

  18. Andersson U, Malmer B, Bergenheim AT, Brännström T, Henriksson R (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21–27

    PubMed  CAS  Google Scholar 

  19. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258:1650–1654

    PubMed  CAS  Google Scholar 

  20. Deeley RG, Cole SP (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 580:1103–1111

    PubMed  CAS  Google Scholar 

  21. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902–5910

    PubMed  CAS  Google Scholar 

  22. Leier I, Jedlitschky G, buchholz U, Keppler D (1994) Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem 220:599–606

    PubMed  CAS  Google Scholar 

  23. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M (1999) Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 14:123–131

    PubMed  CAS  Google Scholar 

  24. Cui Y, Konig J, Buchholz J, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–937

    PubMed  CAS  Google Scholar 

  25. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833–4836

    PubMed  CAS  Google Scholar 

  26. Benyahia B, Huguet S, Decleves X, Mokhtari K, Criniere E, Bernaudin JF, Scherrmann JM, Delattre JY (2004) Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neuro-Oncology 66:65–70

    CAS  Google Scholar 

  27. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, Keppler D (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 129:349–360

    PubMed  CAS  Google Scholar 

  28. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A (2005) Expression of drug resistance protein Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121

    PubMed  CAS  Google Scholar 

  29. Haga S, Hinoshita E, Ikezaki K, Fukui M, Scheffer GL, Uchiumi T, Kuwano M (2001) Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 92:211–219

    PubMed  CAS  Google Scholar 

  30. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670

    PubMed  CAS  Google Scholar 

  31. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33(6) 503–511

    PubMed  CAS  Google Scholar 

  32. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358

    PubMed  Google Scholar 

  33. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145–152

    PubMed  CAS  Google Scholar 

  34. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG (2001) Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 115:257–262

    PubMed  CAS  Google Scholar 

  35. van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ, de Vries EG (2002) Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukaemia. Blood 99:3763–3770

    PubMed  Google Scholar 

  36. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB (2003) The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 17:2085–2087

    PubMed  Google Scholar 

  37. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der V, Leenstra S, Baayen JC, Spliet WG, Troost D (2005) Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849–857

  38. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH (1993) Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475–1479

    PubMed  CAS  Google Scholar 

  39. Chugani DC, Rome LH, Kedersha NL (1993) Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 106:23–29

    PubMed  CAS  Google Scholar 

  40. Slesina M, Inman EM, Rome LH, Volknandt W (2005) Nuclear localization of the major vault protein in U373 cells. Cell Tissue Res 321:97–104

    PubMed  CAS  Google Scholar 

  41. Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Scheffer GL, Scheper RJ (1995) The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55:4214–4219

    PubMed  CAS  Google Scholar 

  42. Scheffer GL, Wijingaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578–582

    PubMed  CAS  Google Scholar 

  43. Hamill DR, Suprenant KA (1997) Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol 190:117–128

    PubMed  CAS  Google Scholar 

  44. Abbondanza C, Rossi V, Roscigno A, Gallo L, Belsito A, Piluso G, Medici N, Nigro V, Molinari AM, Moncharmont B, Puca GA (1998) Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol 141:1301–1310

    PubMed  CAS  Google Scholar 

  45. Kong LB, Siva AC, Rome LH, Stewart PL (1999) Structure of the vault, a ubiquitous cellular component. Structure 7:371–379

    PubMed  CAS  Google Scholar 

  46. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, Geissler K, Lechner K, Pirker R (1998) Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91:1508–1513

    PubMed  CAS  Google Scholar 

  47. Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, Hirayama M, Hino M, Ueda M (2005) Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 68:422–431

    PubMed  CAS  Google Scholar 

  48. Rybarova S, Hajdukova M, Hodorova I, Kocisova M, Boor A, Brabencova E, Kasan P, Biros E, Mojzis J, Mirossay L (2004) Expression of the multidrug resistance associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer. Neoplasma 51:169–174

    PubMed  CAS  Google Scholar 

  49. Aronica E, Gorter JA, van Vliet EA, Spliet WG, van Veelen CW, van Rijen PC, Leenstra S, Ramkema MD, Scheffer GL, Scheper RJ, Sisodiya SM, Troost D (2003) Overexpression of the human major vault protein in gangliogliomas. Epilepsia 44:1166–1175

    PubMed  CAS  Google Scholar 

  50. Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M (2001) Overexpression ofthe human major vault protein in astrocytic brain tumor cells. Int J Cancer 94:377–382

    PubMed  CAS  Google Scholar 

  51. Tews DS, Nissen A, Kulgen C, Gaumann AK (2000) Drug resistance-associated factors in primary and secondary glioblastoma and their precursor tumors. J Neuro-oncology 50:227–237

    CAS  Google Scholar 

  52. Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Cross JH, Scheper RJ, Harding BN, Thom M (2003) Major vault protein a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 44:1388–1396

    PubMed  CAS  Google Scholar 

  53. Wang XM, Xin H, Yang Z, Zhao W, Yang G, Liu J, Tang W, Zhang Q, Han D, Yu R (2004) Clinical study on treatment of advanced stage non-small cell lung cancer by guben xiaoliu capsule. Zhongguo Zhong Xi Yi Jie He Za Zhi 24:986–988

    PubMed  Google Scholar 

  54. Klunder JW, Komdeur R, Van der Graaf WT, De Bont EJ, Hoekstra HJ, Van den Berg E, Molenaar WM (2003) Expression of multidrug resistance–associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance–related protein (LRP) & differentiation. Hum Pathol 34:150–155

    PubMed  CAS  Google Scholar 

  55. Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ (1996) Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 19:191–197

    PubMed  CAS  Google Scholar 

  56. Siva AC, Raval-Fernandes S, Stephen AG, LaFemina MJ, Scheper RJ, Kickhoefer VA, Rome LH (2001) Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 92:195–202

    PubMed  CAS  Google Scholar 

  57. Sasaki T, Hankins GR, Helm GA (2002) Major vault protein/lung resistance-related protein (MVP/LRP) expression in nervous system tumors. Brain Tumor Path 19:59–62

    Google Scholar 

  58. Koda M, Reszec J, Sulkowska M, Kanczuga-Koda L, Sulkowski S (2004) Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer. Ann NY Acad Sci 1030:377–383

    PubMed  CAS  Google Scholar 

  59. Fels C, Schafer C, Huppe B, Bahn H, Heidecke V, Kramm CM, Lautenschlager C, Rainov NG (2000) Bcl-2 expression in higher-grade human glioma: a clinical and experimental study. J Neuro-oncology 48:207–216

    CAS  Google Scholar 

  60. Karmakar S, Weinberg MS, Banik NL, Patel SJ, Ray SK (2006) Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience 141:1265–1280

    PubMed  CAS  Google Scholar 

  61. Huang DC, O’Reilly LA, Strasser A, Cory S (1997) The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16:4628–4638

    PubMed  CAS  Google Scholar 

  62. Vairo G, Innes KM, Adams JM (1996) Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13:1511–1519

    PubMed  CAS  Google Scholar 

  63. Greider C, Chattopadhyay A, Parkhurst C, Yang E (2002) BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 21:7765–7775

    PubMed  CAS  Google Scholar 

  64. Bélanger S, Côté M, Lane D, L’Espérance S, Rancourt C, Piché A (2005) Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells. Gynecol Oncol 97:796–806

    PubMed  Google Scholar 

  65. Tyagi D, Sharma BS, Gupta SK, Kaul D, Vasishta RK, Khosla VK (2002) Expression of Bcl2 proto-oncogene in primary tumors of the central nervous system. Neurol India 50:290–294

    PubMed  CAS  Google Scholar 

  66. Lu Z, Wu Z, Mo Y (2006) Regulation of bcl-2 expression by Ubc9. Exp Cell Res 312:1865–1875

    PubMed  CAS  Google Scholar 

  67. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 Gne transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95:2633–2643

    PubMed  CAS  Google Scholar 

  68. Riger J, Roth W, Glaser T, Winter S, Rieger L, Dichgans J, Weller M (1999) Glioblastoma multiforme: mechanisms of resistance to chemotherapy. Neurol Psychiatry Brain Res 7:37–46

    Google Scholar 

  69. Korshunov A, Golanov A, Sycheva R, Pronin I (1999b) Prognostic value of the immunoexpression of chemoresistance-related proteins in cerebral goioblastomas: an analysis of 168 cases. J Clin Pathol 52:574–580

    Article  PubMed  CAS  Google Scholar 

  70. Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC (1997) bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol 94:369–375

    PubMed  CAS  Google Scholar 

  71. Prowit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G (1995) Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9:1191–1198

    Google Scholar 

  72. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ (1996) Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456–459

    PubMed  CAS  Google Scholar 

  73. Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M (2002) BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol 56:43–49

    PubMed  Google Scholar 

  74. Bruce WR, Van Der Gaag H (1963) A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199:79–80

    PubMed  CAS  Google Scholar 

  75. Al-Hajj M, Wicha MS, ito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci US 100:3983–3988

    CAS  Google Scholar 

  76. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 94:5320–5325

    PubMed  CAS  Google Scholar 

  77. Challen GA, Little MH (2006) A side order of stem cells: the SP phenotype. Stem Cells 24:3–12

    PubMed  Google Scholar 

  78. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct ‘‘side population’’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233

    PubMed  CAS  Google Scholar 

  79. Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101:781–786

    PubMed  CAS  Google Scholar 

  80. Wang JC, Dick JE (2005) Cancer stem cells: lessons from leukemia. Trends Cell Biol 15:494–501

    PubMed  CAS  Google Scholar 

  81. Miller SJ, Lavker RM, Sun TT (2005) Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 1756:25–52

    PubMed  CAS  Google Scholar 

  82. Fomchenko EI, Holland EC (2005) Stem cells and brain cancer. Exp Cell Res 306:323–329

    PubMed  CAS  Google Scholar 

  83. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111

    PubMed  CAS  Google Scholar 

  84. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85–94

    PubMed  CAS  Google Scholar 

  85. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028–1034

    PubMed  CAS  Google Scholar 

  86. Cai J, Cheng A, Luo Y, Lu C, Mattson MP, Rao MS, Furukawa K (2004) Membrane properties of rat embryonic multipotent neural stem cells. J Neurochem 88:212–226

    Article  PubMed  CAS  Google Scholar 

  87. Platet N, Mayo J, Berger F, Hérodin F, Wion D (2007) Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Lett 581:1435–1440

    PubMed  CAS  Google Scholar 

  88. Robey RW, Polgar O, Deeken J, To KW, Bates SE (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39–57

    PubMed  CAS  Google Scholar 

  89. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 65:6207–6219

    PubMed  CAS  Google Scholar 

  90. Wei L, Cui L, Snider J, Rivkin M, Yu SS, Lee CS, Adams LD, Gottlieb DI, Johnson Jr EM, Yu SP, Choi DW (2005) Transplantation of embryonic stem cells overexpressing Bcl-2 promotes functional recovery after transient cerebral ischemia. Neurobiol Dis 19:183–193

    PubMed  CAS  Google Scholar 

  91. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67–71

    PubMed  Google Scholar 

  92. Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM (2002) Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173–180

    PubMed  CAS  Google Scholar 

  93. Matsumoto Y, Miyake K, Kunishio K, Tamiya T, Seigo N (2004) Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides. J Med Invest 51:194–201

    PubMed  Google Scholar 

  94. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374–383

    PubMed  CAS  Google Scholar 

  95. Kitazono M, Okumura H, Ikeda R, Sumizawa T, Furukawa T, Nagayama S, Seto K, Aikou T, Akiyama S (2001) Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer 91:126–131

    PubMed  CAS  Google Scholar 

  96. Manero F, Gautier F, Gallenne T, Cauquil N, Grée D, Cartron PF, Geneste O, Grée R, Vallette FM, Juin P (2006) The small organic compound HA14–1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66:2757–2764

    PubMed  CAS  Google Scholar 

  97. Zhu CJ, Li YB, Wong MC (2003) Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosesitivity of human malignant glioma cells. J Neurosci Res 74:60–66

    PubMed  CAS  Google Scholar 

  98. Baguley BC (2006) Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Patents Anti-Cancer Drug Discov 1:121–127

    CAS  Google Scholar 

  99. Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO, Aboody KS (2003) Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin Hum Gene Ther 14:1777–1785

    PubMed  CAS  Google Scholar 

  100. Irvin DK, Yuan X, Zhaohui Z, Tunici P, Yu JS (2006) Neural stem cells – a promising potential therapy for brain tumors. Curr Stem Cell Res Ther 1:79–84

    Google Scholar 

  101. Sell S (2004) Stem cell origin of cancer and differentiation therapy Crit Rev Oncol/Hematol 51:1–28

    Google Scholar 

  102. Tunici P, Irvin D, Liu G, Yuan X, Zhaohui Z, Ng H, Yu JS (2006) Brain tumor stem cells: new targets for clinical treatments? Neurosurg Focus 20:E27

    PubMed  Google Scholar 

  103. Rittierodt M, Tschernig T, Harada K (2004) Modulation of multidrug-resistance-associated p-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 71:123–128

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Dr Leroy Shervington for editing the script and Andrew Bamber, David Burnham, Clare Christopher and Christopher Clark for their contribution. This work was supported by a grant from the University of Central Lancashire.

Author information

Authors and Affiliations

  1. Brain Tumour North West, Faculty of Science, University of Central Lancashire, Preston, UK

    Chen Lu & Amal Shervington

Authors
  1. Chen Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amal Shervington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amal Shervington.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, C., Shervington, A. Chemoresistance in gliomas. Mol Cell Biochem 312, 71–80 (2008). https://doi.org/10.1007/s11010-008-9722-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-008-9722-8

Keywords

Search

Navigation